Literature DB >> 25918144

The efflux pump SmeDEF contributes to trimethoprim-sulfamethoxazole resistance in Stenotrophomonas maltophilia.

María Blanca Sánchez1, José Luis Martínez2.   

Abstract

Trimethoprim-sulfamethoxazole (co-trimoxazole) is one of the antimicrobials of choice for the treatment of Stenotrophomonas maltophilia infections. The analysis of mutants either lacking or overexpressing the efflux pump SmeDEF shows that this efflux pump contributes to intrinsic and acquired co-trimoxazole resistance in S. maltophilia. Since SmeDEF can extrude a variety of antibiotics, selection with such antimicrobials, including quinolones, might also select for S. maltophilia co-trimoxazole resistance.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25918144      PMCID： PMC4468665          DOI： 10.1128/AAC.00714-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  19 in total

Review 1.  Mutation frequencies and antibiotic resistance.

Authors:  J L Martinez; F Baquero
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

2.  Expression of multidrug efflux pump SmeDEF by clinical isolates of Stenotrophomonas maltophilia.

Authors:  A Alonso; J L Martinez
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

3.  SmeC, an outer membrane multidrug efflux protein of Stenotrophomonas maltophilia.

Authors:  Xian-Zhi Li; Li Zhang; Keith Poole
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

4.  Cloning and characterization of SmeDEF, a novel multidrug efflux pump from Stenotrophomonas maltophilia.

Authors:  A Alonso; J L Martínez
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

5.  Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit.

Authors:  Helio S Sader; Ronald N Jones; Michael J Dowzicky; Thomas R Fritsche
Journal:  Diagn Microbiol Infect Dis       Date:  2005-07       Impact factor: 2.803

6.  Multidrug resistance in clinical isolates of Stenotrophomonas maltophilia: roles of integrons, efflux pumps, phosphoglucomutase (SpgM), and melanin and biofilm formation.

Authors:  S-J Liaw; Y-L Lee; P-R Hsueh
Journal:  Int J Antimicrob Agents       Date:  2009-11-18       Impact factor: 5.283

7.  Comparisons between patients with trimethoprim-sulfamethoxazole-susceptible and trimethoprim-sulfamethoxazole-resistant Stenotrophomonas maltophilia monomicrobial bacteremia: A 10-year retrospective study.

Authors:  Ching-Hsun Wang; Jung-Chung Lin; Hsin-An Lin; Feng-Yee Chang; Ning-Chi Wang; Sheng-Kang Chiu; Te-Yu Lin; Ya-Sung Yang; Li-Ping Kan; Chin-Hsuan Yang; Ming-Chin Chan; Kuo-Ming Yeh
Journal:  J Microbiol Immunol Infect       Date:  2014-07-28       Impact factor: 4.399

8.  A function of SmeDEF, the major quinolone resistance determinant of Stenotrophomonas maltophilia, is the colonization of plant roots.

Authors:  Guillermo García-León; Alvaro Hernández; Sara Hernando-Amado; Peyman Alavi; Gabriele Berg; José Luis Martínez
Journal:  Appl Environ Microbiol       Date:  2014-08       Impact factor: 4.792

9.  Contribution of resistance-nodulation-cell division efflux systems to antibiotic resistance and biofilm formation in Acinetobacter baumannii.

Authors:  Eun-Jeong Yoon; Yassine Nait Chabane; Sylvie Goussard; Erik Snesrud; Patrice Courvalin; Emmanuelle Dé; Catherine Grillot-Courvalin
Journal:  MBio       Date:  2015-03-24       Impact factor: 7.867

10.  The complete genome, comparative and functional analysis of Stenotrophomonas maltophilia reveals an organism heavily shielded by drug resistance determinants.

Authors:  Lisa C Crossman; Virginia C Gould; J Maxwell Dow; Georgios S Vernikos; Aki Okazaki; Mohammed Sebaihia; David Saunders; Claire Arrowsmith; Tim Carver; Nicholas Peters; Ellen Adlem; Arnaud Kerhornou; Angela Lord; Lee Murphy; Katharine Seeger; Robert Squares; Simon Rutter; Michael A Quail; Mari-Adele Rajandream; David Harris; Carol Churcher; Stephen D Bentley; Julian Parkhill; Nicholas R Thomson; Matthew B Avison
Journal:  Genome Biol       Date:  2008-04-17       Impact factor: 13.583
View more
  16 in total

1.  Type II Secretion-Dependent Degradative and Cytotoxic Activities Mediated by Stenotrophomonas maltophilia Serine Proteases StmPr1 and StmPr2.

Authors:  Ashley L DuMont; Sara M Karaba; Nicholas P Cianciotto
Journal:  Infect Immun       Date:  2015-07-13       Impact factor: 3.441

Review 2.  MDR Pumps as Crossroads of Resistance: Antibiotics and Bacteriophages.

Authors:  Pavel A Nazarov
Journal:  Antibiotics (Basel)       Date:  2022-05-30

3.  Stenotrophomonas maltophilia Serine Protease StmPr1 Induces Matrilysis, Anoikis, and Protease-Activated Receptor 2 Activation in Human Lung Epithelial Cells.

Authors:  Ashley L DuMont; Nicholas P Cianciotto
Journal:  Infect Immun       Date:  2017-11-17       Impact factor: 3.441

4.  Overexpression of the Efflux Pumps SmeVWX and SmeDEF Is a Major Cause of Resistance to Co-trimoxazole in Stenotrophomonas maltophilia.

Authors:  María Blanca Sánchez; José Luis Martínez
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191

5.  Stenotrophomonas maltophilia produces an EntC-dependent catecholate siderophore that is distinct from enterobactin.

Authors:  Megan Y Nas; Nicholas P Cianciotto
Journal:  Microbiology       Date:  2017-10-06       Impact factor: 2.777

6.  Stenotrophomonas maltophilia Susceptibility Testing Challenges and Strategies.

Authors:  Daniel D Rhoads
Journal:  J Clin Microbiol       Date:  2021-08-18       Impact factor: 5.948

7.  Advances in the Microbiology of Stenotrophomonas maltophilia.

Authors:  Joanna S Brooke
Journal:  Clin Microbiol Rev       Date:  2021-05-26       Impact factor: 50.129

Review 8.  Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options.

Authors:  Ya-Ting Chang; Chun-Yu Lin; Yen-Hsu Chen; Po-Ren Hsueh
Journal:  Front Microbiol       Date:  2015-09-02       Impact factor: 5.640

9.  Evaluation of Trimethoprim/Sulfamethoxazole (SXT), Minocycline, Tigecycline, Moxifloxacin, and Ceftazidime Alone and in Combinations for SXT-Susceptible and SXT-Resistant Stenotrophomonas maltophilia by In Vitro Time-Kill Experiments.

Authors:  Chuanqi Wei; Wentao Ni; Xuejiu Cai; Jin Zhao; Junchang Cui
Journal:  PLoS One       Date:  2016-03-21       Impact factor: 3.240

10.  Frequency and Genetic Determinants of Tigecycline Resistance in Clinically Isolated Stenotrophomonas maltophilia in Beijing, China.

Authors:  Jin Zhao; Yunxi Liu; Yi Liu; Dong Wang; Wentao Ni; Rui Wang; Youning Liu; Bo Zhang
Journal:  Front Microbiol       Date:  2018-03-26       Impact factor: 5.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.